Table 1.
Baseline characteristics.
|
|
Patients (N=53) | |
| Age (year), mean (SD) | 39.8 (11.7) | |
| Female, n (%) | 24 (45.3) | |
| Ethnicity, n (%) | ||
|
|
Caucasian | 36 (67.9) |
|
|
Asian | 8 (15.1) |
|
|
Hispanic/Latinx | 6 (11.3) |
|
|
African American | 3 (5.7) |
| Diabetes type, n (%) | ||
|
|
Type 1 | 35 (66.0) |
|
|
Type 2 | 18 (34.0) |
| Commercially insured, n (%) | 52 (98.1) | |
| Complications, n (%) | 20 (37.7) | |
|
|
Peripheral neuropathy | 10 (18.9) |
|
|
Diabetic retinopathy | 11 (20.8) |
|
|
Nephropathy | 7 (13.2) |
|
|
Cardiovascular disease | 1 (1.9) |
| Duration of care (months), median (IQR) | 11 (5, 18) | |
| HbA1ca (%; n=41), median (IQR) | 8.5 (7.5, 11.2) | |
|
|
<8%, n (%) | 17 (41.5) |
|
|
8%-10%, n (%) | 10 (24.4) |
|
|
>10%, n (%) | 14 (34.1) |
| Time in rangeb (%), median (IQR) | 53.0 (40.9, 61.7) | |
|
|
0%-30%, n (%) | 11 (20.8) |
|
|
30%-50%, n (%) | 12 (22.6) |
|
|
50%-60%, n (%) | 13 (24.5) |
|
|
60%-70%, n (%) | 17 (32.1) |
| Time below rangec (%), median (IQR) | 0.9 (0.2, 2.5) | |
|
|
0%-1%, n (%) | 28 (52.8) |
|
|
1%-4%, n (%) | 18 (34.0) |
|
|
>4%, n (%) | 7 (13.2) |
| Treatment with insulin, n (%) | 44 (83.0) | |
|
|
Injection | 25 (56.8) |
|
|
Pump | 19 (43.2) |
aHBA1c: hemoglobin A1c.
bTime in range defined as % of time glucose falls between 70-180 mg/dL over 28 days.
cTime below range defined as % of time glucose falls below 70 mg/dL over 28 days.